Rocket Pharma's Pivotal Danon Disease Trial Resumes, KRESLADI™ PDUFA Set for March 28, 2026

summarizeSummary

Rocket Pharmaceuticals reported Q4/FY2025 financial results, confirmed its cash runway into Q2 2027, and provided positive updates on its key gene therapy programs, including the resumption of the pivotal Danon disease trial and a PDUFA date for KRESLADI™.

check_boxKey Events

• Pivotal Danon Disease Trial Resumes

  The FDA lifted the clinical hold on the RP-A501 Phase 2 trial for Danon disease in August 2025, with dosing of additional patients anticipated in the first half of 2026.

• KRESLADI™ PDUFA Date Set

  The BLA resubmission for KRESLADI™ (marnetegragene autotemcel) for severe LAD-I has been accepted, with a Prescription Drug User Fee Act (PDUFA) target action date of March 28, 2026.

• Extended Cash Runway

  Rocket Pharmaceuticals reported $188.9 million in cash, cash equivalents, and investments as of December 31, 2025, which is expected to fund operations into the second quarter of 2027.

• Reduced Operating Expenses

  Research and development expenses decreased by $29.2 million and general and administrative expenses decreased by $15.5 million for the twelve months ended December 31, 2025, reflecting disciplined resource allocation and organizational realignment.

auto_awesomeAnalysis

This filing provides critical updates for Rocket Pharmaceuticals, addressing previous concerns and highlighting significant progress in its pipeline. The resumption of the pivotal Phase 2 trial for RP-A501 in Danon disease, following the lifting of a clinical hold, de-risks a key program. Additionally, the March 28, 2026 PDUFA date for KRESLADI™ creates a near-term catalyst for potential approval and a Priority Review Voucher. The reported cash position and extended operational runway into Q2 2027 provide financial stability, reflecting the impact of recent cost-cutting measures. Investors should monitor the upcoming PDUFA decision and further progress in the Danon disease trial.